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1  |  INTRODUC TION
Birth represents a relatively dramatic transition from an environ-
ment with a low microbial burden to one abundant in commensal and 
potentially pathogenic challenges that the neonatal immune system 
must be able to respond to. Immune responses in preterm and term 
neonates differ from those of adults, generally being characterized 
as diminished, tolerant or Th skewed although we must be mindful 
that these are highly evolved, stage of life appropriate responses. 
Efforts to clarify the phenotypes and mechanisms prevalent at this 
time are ongoing so that we can better understand the significance 
of differences at this stage of development for long- term health. 
The need to understand how the neonatal immune response dif-
fers to that of adults is driven by the mortality and morbidity as-
sociated with infection and sepsis in newborns and infants and 
the need for protective vaccine responses that can mitigate these. 
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Abstract
Immune responses of neonates differ markedly to those of adults, with skewed cy-
tokine phenotypes, reduced inflammatory properties and drastically diminished 
memory function. Recent research efforts have started to unravel the role of cellu-
lar metabolism in determining immune cell fate and function. For studies in humans, 
much of the work on metabolic mechanisms underpinning innate and adaptive im-
mune responses by different haematopoietic cell types is in adults. Studies investigat-
ing the contribution of metabolic adaptation in the unique setting of early life are just 
emerging, and much more work is needed to elucidate the contribution of metabo-
lism to neonatal immune responses. Here, we discuss our current understanding of 
neonatal immune responses, examine some of the latest developments in neonatal 
immunometabolism and consider the possible role of altered metabolism to the dis-
tinctive immune phenotype of the neonate. Understanding the role of metabolism in 
regulating immune function at this critical stage in life has direct benefit for the child 
by affording opportunities to maximize immediate and long- term health. Additionally, 
gaining insight into the diversity of human immune function and naturally evolved im-
munometabolic strategies that modulate immune function could be harnessed for a 
wide range of opportunities including new therapeutic approaches.
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Recent decades have also seen growing appreciation that neonatal 
immune phenotypes, shaped predominantly by environmental fac-
tors during pregnancy, are linked to the later development of non- 
communicable immunoinflammatory diseases.1– 3 Finally, while the 
therapeutic capacity of umbilical cord blood is already being har-
nessed through transplantation, there is growing appreciation of the 
wider regenerative capacity of neonatal immune cells, for example in 
the regeneration of heart tissue.4 Given this diversity, there is a real 
need to elucidate the mechanisms that uniquely programme neona-
tal immune cell phenotype.
The development and maturation of lymphoid progenitors during 
foetal and early post- natal life are influenced by a multitude of fac-
tors including cytokine profiles, transcription factors, expression of 
surface proteins, prostaglandins produced by the placenta and al-
tered levels of metabolites, such as adenosine, in neonatal plasma.5– 7 
Maternal immune status during pregnancy also appears to affect 
neonatal and infant immune development. For example, infants of 
mothers who suffer from allergic disease have reduced interleukin 
(IL)- 6 production and p38 mitogen- activated protein kinase (MAPK) 
phosphorylation compared with age- matched healthy controls.8 It 
also has been long recognized that maternal and neonatal nutrition 
have lasting effects on immune development, contributing to the 
development of allergic disease, metabolic syndrome and chronic in-
flammatory conditions.9 Energy demands in early life are extremely 
high with little to no energy, especially fatty acids and proteins, re-
serves. The metabolic and energetic demands required for growth in 
early life severely limit nutrient availability for highly energetically 
demanding immune responses.10 Disease tolerance, wherein the 
goal is to limit disease immunopathology versus the pathogen per 
se, is suggested as an evolved method of host defence in early life to 
limit harm to the host in the face of these reduced energy reserves. 
Energy demands of neonates and the disease tolerance hypothesis 
have been reviewed extensively elsewhere.10– 14
Immunometabolism is a relatively recently emerged field of re-
search that seeks to elucidate the crucial role metabolic pathways 
have in shaping immune cell fate and function. The activation and 
function of most immune cells is dependent on metabolic repro-
gramming to a state of aerobic glycolysis to enable effector func-
tion. In this setting, the primary fuel is glucose which is metabolized 
through the central metabolism pathways of glycolysis to pyruvate 
(Figure 1). Aerobic glycolysis rapidly generates adenosine triphos-
phate (ATP) via substrate- level phosphorylation as well as reducing 
nicotinamide adenine dinucleotide (NAD)+ to NADH. Many cells 
also convert pyruvate to lactate to recycle NADH, thus maintain-
ing glycolytic flux. Glucose metabolism also supports activation of 
immune cells by generating anabolic intermediates required for cell 
growth, division and function.15 Pyruvate enters the Krebs cycle via 
conversion to acetyl- CoA. NADH and flavin adenine dinucleotide 
(FAD)H2 are the major products of the Krebs cycle, which support 
oxidative phosphorylation (OXPHOS) by transfer of electrons to the 
electron transport chain. Catabolism in the Krebs cycle also sup-
ports cell growth, producing the anabolic building blocks for amino 
acids and lipids. To support catabolism, the Krebs cycle must be 
replenished, in a process called anaplerosis, converting various sub-
strates such as the amino acid glutamine into Krebs cycle intermedi-
ates (Figure 1). Fatty acid oxidation (FAO) also feeds into the Krebs 
cycle via acetyl- CoA as well as supporting OXPHOS through NADH 
and FADH2 (Figure 1).
The differential utilization of fuels, including in competition with 
other cells in the tissue microenvironment, can impact on cell fate 
and function.16 We suggest that immunometabolism provides a 
framework for understanding phenotypic and functional differences 
in the neonatal and adult immune systems and also between neo-
nates linked to individual disease susceptibility. While data support-
ing this are emerging, these studies are still very much in their early 
days and there are many unanswered questions. In this review, we 
will discuss the current understanding of differences between neo-
nate and adult immune responses; how metabolism may influence 
these changes and the further work that is required.
2  |  INNATE IMMUNE RESPONSES
The innate immune system provides front- line cellular and humoral 
defence through the release of cytokines and other mediators that 
amplify the immune response, recruitment of first responders and 
education of the adaptive immune response to help counter the 
threat and develop immunological memory. These processes de-
mand energy and biosynthetic intermediates that are generated via 
cellular metabolic pathways.
2.1  |  Neutrophils
Neutrophils comprise 70% of the leukocytes in blood. They extrav-
asate from the blood and quickly travel to the site of insult along 
a chemokine gradient typically released by tissue- resident mac-
rophages. Once in the tissues, neutrophils engulf and kill pathogens 
Key Message
Despite great advances in our understanding of immu-
nometabolism, few advances have been made in apply-
ing these insights to human neonatal immune responses. 
Emerging evidence suggests a central role for metabolism 
in defining the immune responses of neonates and these 
could underpin functional differences implicated in the 
development of atopic disease for example. Here, we sum-
marize the latest findings on immunometabolism and high-
light gaps in the literature with specific regard to neonates, 
exploring connections between metabolism and neonatal 
immune phenotype. A better understanding of immuno-
metabolism in neonates could have impacts ranging from 
improved health to new regenerative treatments.
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before undergoing controlled apoptosis. In neonates, there is a 
transient rise in neutrophil frequency shortly before birth, as meas-
ured by neutrophil- derived soluble FcRIII (CD16) levels in plasma of 
preterm and term infants. However, neutrophil frequency reduces 
again shortly after birth to levels below that of adults, contributing 
to diminished first responder function.17,18 Neonatal neutrophils 
also have reduced functional capacity; their chemotaxis response 
is reduced through slower velocities and lower expression of the 
surface adhesion molecules L- selectin and Mac1, contributing 
to a near 50% reduction in neutrophil transmigration to the site 
of infection.19,20 Lower expression of TLR4 and defective down-
stream signalling by myeloid differentiation primary response 88 
(MyD88) and p38 MAPK from TLR4 and TLR2 impair neutrophil 
response.21 High levels of adenosine in neonatal blood increase cy-
clic adenosine monophosphate (cAMP) leading to protein kinase A 
(PKA)- dependent/TLR- independent inhibition of tumour necrosis 
factor (TNF)α.7 For neonatal neutrophils, some reports also show 
reduced capacity, or entire loss, of their primary effector func-
tions of phagocytosis, neutrophilic oxidative burst and formation 
of neutrophil extracellular traps.17,22 All of these are energetically 
demanding requiring high levels of glycolysis, the main metabolic 
pathway in neutrophils and, to a lesser extent, glutaminolysis to 
support them.23,24 Inhibition of these metabolic pathways can 
entirely prevent effector functions of adult neutrophils.23,24 For 
instance, NETosis is dependent on lactate derived from glycolysis 
in both NOX- dependent and independent pathways.25 Whether 
changes in neonatal neutrophil metabolism are responsible for 
their decreased effector functions has not been elucidated but 
clearly warrants investigation. Ketone metabolism may be a key 
pathway to consider as ketone bodies provide an important fuel 
for neonates26 and may be required for effector functions like NET 
formation.27
2.2  |  Eosinophils
Elevated eosinophil counts in newborns have been reported with 
infection in preterm infants and have been linked to later atopy.28 
Little is known about the metabolic functions of eosinophils in gen-
eral though experiments in adults show that eosinophils do use gly-
colytic metabolism.29 However, eosinophil metabolic plasticity was 
demonstrated recently with both increased glucose- derived lactate 
production, when reactive oxygen species are inhibited, and gen-
eration of TCA intermediates from both glucose and glutamine, on 
cytokine stimulation.30 Further work is needed to explore the role 
of metabolism in determining eosinophil function and to evaluate 
F I G U R E  1  Basic metabolism and metabolic signalling pathways. A) Glucose, amino acids and fatty acids are the major metabolites utilized 
by cells of the immune system. These metabolites feed into the TCA cycle, through glycolysis, fatty acid oxidation or other metabolic 
pathways. Oxidation of these metabolites, through these metabolic pathways, generates ATP via substrate- level phosphorylation or 
through the electron transport chain. B) Metabolic pathways are influenced by a number of external stimuli including cytokines, specialized 
receptors, such as the T- cell receptor, and PAMPs. Resultant signalling cascades via PI3K/AKT increase mTOR signalling, in turn enhancing 
metabolic pathways typically associated with pro- inflammatory responses. AMPK, on the other hand, inhibits mTOR signalling and 
upregulates metabolic pathways associated with anti- inflammatory responses. Created using biore nder.com
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whether there is any role for altered metabolism in eosinophilia in 
neonates.
2.3  |  Type 2 innate lymphoid cells
Type 2 innate lymphoid cells (ILC2) are found at epithelial barriers 
such as in the lung and are a major source of IL- 5 that can induce 
eosinophilia. ILC2 numbers rapidly increase in the lungs after birth, 
peaking at three times that of adults by day 10 but quickly decreasing 
to adult levels.31 Among the ILC subsets, ILC2 is the most function-
ally mature compared with ILC1 and ILC3.32 The alarmin IL- 33, pro-
duced by epithelial cells, recruits eosinophils and ILC2 to the lungs 
and acts as a potent activator of ILC2.31 Despite higher IL- 33 levels 
in neonates, ILC2 activation is not as potent as in adults. The high 
levels of endogenous IL- 33 in the neonatal lung are suggested to 
train the ILC2 response for a more efficient response to challenges in 
later life.33 It is also worth noting that IL- 33 signalling via ST2 under 
neonatal hypoxia is important for the expression of asthma- related 
genes.34 Given that hypoxia- inducible factor- α strongly stimulates 
glycolysis, this suggests that a highly glycolytic programme of ILC2s 
in early life might have harmful effects.
In adults, ILC2 demonstrates the capacity to augment mitochon-
drial respiration above basal conditions when activated with IL- 33. 
Arg1 is suggested as key to the function of ILC2 as inhibition leads 
to decreased production of effector cytokines such as IL- 5 and IL- 13 
accompanied by significantly reduced glycolytic capacity.35 Evidence 
indicating a glycolytic programme in ILC2 comes from experiments 
inhibiting glycolysis via PD1 which resulted in decreased expression 
of effector cytokines and reduced proliferation and cell survival.36 
Conflicting evidence using helminth infection in mouse models sug-
gests fatty acid oxidation, rather than glycolysis, is necessary for 
expansion and cytokine production by ILC2.37 Differing methods of 
ILC2 activation as well as differences between mouse and human 
responses may account for the conflicting results with further ex-
periments needed to clarify this. Furthermore, given that neonates 
exhibit less potent responses than adults, despite increased IL- 
33 signalling and the emerging role of metabolism in ILC2 effector 
cytokine production, an investigation into the metabolic function of 
neonatal ILC2 is warranted.
2.4  |  Monocytes/macrophages
Monocytes and macrophages perform key innate roles in clearing 
threats through phagocytosis and oxidative killing and contrib-
ute to adaptive responses through antigen presentation to T cells. 
Monocytes are better studied in neonates compared with mac-
rophages as they can be isolated from blood. Studies of pattern rec-
ognition receptors are essentially restricted to TLRs, and neonates 
have similar expression levels compared with adults. However, neo-
natal monocytes have impaired TLR- mediated production of TNFα 
and other pro- inflammatory cytokines.38 Reduced expression of 
TNFα has been associated with high levels of adenosine, a metabo-
lite with immunomodulatory properties. Adenosine acts via the A3 
adenosine receptor inducing production of the secondary messen-
ger cAMP which inhibits TLR- mediated TNFα production.7 Reduced 
MyD88 expression has also been implicated in failure to produce 
pro- inflammatory cytokines such as TNFα and IL- 12p70. While limit-
ing innate immune responses, this reduced capacity to produce key 
cytokines along with reduced expression of human leukocyte anti-
gen (HLA)- DR and co- stimulatory molecules such as CD40 at the 
basal state also affect the ability to activate T cells.39,40 However, 
after LPS treatment, expression of co- stimulatory molecules, MHC- II 
and CD80, does not differ significantly from adults.41 Altered cellu-
lar metabolism is now emerging as a critical regulator of neonatal 
monocyte function, especially cytokine production. Whole- blood 
transcriptomic data suggest significantly increased activity in glu-
cose and cholesterol metabolic pathways. Three glycolytic regula-
tory nodes— glucose transporter GLUT3 and glycolytic enzymes 6 
phosphofructo- 2- kinase and hexokinase 3— were upregulated in re-
sponse to infection, but the cellular provenance of these was not 
identified.42 Monocytes isolated from term and preterm umbilical 
cord blood have reduced glycolysis compared with adults. Glycolysis 
was required for cytokine production but not for phagocytosis which 
was unaffected by inhibition of glycolysis using 2- deoxy- D- glucose 
(2DG).5 More recently, umbilical cord blood monocyte– derived mac-
rophages were also shown to be broadly defective in glycolysis and 
to exhibit reduced oxidative phosphorylation compared with adult 
peripheral blood monocyte– derived macrophages.43 IL- 10- polarized 
umbilical cord blood– derived macrophages had adult- like levels of 
OXPHOS but reduced glycolysis. As for adenosine, circulating fac-
tors in umbilical cord blood seem to mediate this effect as treating 
adult peripheral blood– derived macrophages with cord blood plasma 
dramatically inhibited glycolysis. This was attributed to high expres-
sion of the S100 proteins S100A8/A9 in neonates.43 Furthermore, 
cord blood monocyte– derived macrophages have reduced expres-
sion of co- stimulatory CD80 and CD86 and reduced capacity to 
stimulate T cells.44
Mammalian target of rapamycin (mTOR) and its downstream 
targets are essential for metabolic reprogramming of macrophages, 
with signalling through this pathway required for glycolytic repro-
gramming (Figure 1).45 Surprisingly, mTOR transcripts are elevated 
in cord blood compared with adult blood– derived macrophages 
but total mTOR protein expression and mTOR phosphorylation 
are both reduced compared with adults. This disparity suggests 
post- transcriptional regulation of mTOR expression in neonates. 
Downstream targets of mTORC1, ribosomal protein s6 and eukary-
otic translation initiation factor 4E- binding protein 1 also showed 
reduced expression and phosphorylation respectively compared 
with adults.43
The findings summarized above highlight that monocyte metab-
olism is critical to regulating the neonatal immune response. As vari-
ation in TLR- mediated cytokine production at birth has been linked 
to maternal health status and later development of allergic disease 
by the child,46– 48 identifying possible metabolic determinants of this 
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might provide insight into why this occurs and how it might be pre-
vented or rectified. Therefore, links between metabolic control of 
innate cell function in neonates and immediate and long- term health 
outcomes deserve further investigation.
2.5  |  Natural killer cells
Natural killer (NK) cells are crucial to the resolution of acute res-
piratory viral infections such as those caused by influenza or res-
piratory syncytial virus. Mature NK cells can be subdivided into two 
main subsets, a CD56bright CD16dim subset, which produces high 
amounts of inflammatory cytokines, and CD56dim CD16bright, 
which are a highly cytotoxic subset.49 NK cell function is regulated 
by the balance of inhibitory and activating receptors expressed on 
the cell surface especially HLA- E binding members of the CD94/
NKG2 family such as inhibitory NKG2A and stimulatory NKG2C 
and NKG2D.50 Neonatal NK cells have been shown consistently to 
have reduced degranulation and cytotoxicity as well as reduced in-
terferon (IFN)γ production.51,52 This seems to be despite high de-
grees of similarity in phenotypic markers in comparison with adults, 
though upregulated expression of inhibitory NKG2A on cord blood 
CD56dim NK cells has been suggested to contribute to these re-
duced responses although this might be counterbalanced by upregu-
lated NKG2D.50,53
Emerging data about the role of metabolism in NK cell function 
identify key pathways that should be investigated in the neonate. 
Murine NK cells rely on OXPHOS for homeostatic function and 
acute responses such as cytokine production, following short- term 
activation.54 In human NK cells, early cytokine responses can occur 
independent of glucose.55 Long- term activation of NK cells upregu-
lates both OXPHOS and glycolysis to meet the metabolic demands 
of effector function 56 supported by increased expression of nutri-
ent transporters such as GLUT1, CD98 and CD71 following stimula-
tion.56,57 Inhibition of OXPHOS limits NK cell IFNγ production and 
degranulation, whereas glycolytic inhibition impairs cytotoxic func-
tions such as target cell killing and degranulation.56,58 Regulatory 
factor mTORC1 is required for successful NK cell function— inhibition 
of its activity in murine NK cells prevents the upregulation of glycol-
ysis needed for granzyme B and IFNγ production.59 mTORC1 activ-
ity is also needed for NKG2D- mediated IFNγ production in human 
NK cell subsets.57 Given the importance of metabolic reprogram-
ming for the function of NK cells as summarized here, metabolic 
differences may be a key determinant of altered function of neonatal 
NK cells.
Given the possibility that metabolism may underpin changes seen 
in neonatal NK cell function, this leads to the question of what local 
environmental factors might regulate NK cell metabolism in early life. 
Various factors abundant in the neonatal circulation like adenosine 
and S100A8/A9 as discussed above might contribute to this along 
with TGFβ which is a candidate for regulating NK cell metabolism. 
TGFβ is abundant in utero and during early life60– 62 and is known to 
affect NK cell function including inhibition of cytotoxicity63,64 and of 
CD16- induced IFNγ production through SMAD3 repression of tran-
scription.63 These inhibitory effects of TGFβ have been attributed 
to its role in inhibiting cellular metabolism. In short- term activation 
assays, IL- 15- stimulated mouse and human NK cells treated with 
TGFβ had reduced mTOR signalling (primarily mTORC1), impaired 
cellular metabolism and reduced cytokine production.65 While this 
also might be mTORC1 independent,66 it seems that TGFβ inhibits 
metabolic pathways, such as glycolysis and OXPHOS, in human NK 
cells. As efforts are made to understand neonatal NK cell metab-
olism, parallel efforts should consider the role of TGFβ and similar 
immunomodulatory cytokines.
2.6  |  Dendritic cells
Dendritic cells (DCs) have a critical role in educating and priming the 
adaptive immune response through integrating signals from the local 
microenvironment to modulate MHC, co- stimulatory molecules and 
cytokine expression, thereby orchestrating T- cell activation and ef-
fector function. The two major groups of DCs in humans are classi-
cal (cDCs) and plasmacytoid (pDCs). These are typically found in a 
ratio of around 3:1 in adult peripheral blood but occur at a ratio of 
1:3 (cDCs to pDCs) in umbilical cord blood.67 Neonatal monocyte– 
derived DCs have been described to favour the Th2- biased cytokine 
effector function of neonates (Figure 2).68 This might reflect that, 
despite similar expression of TLRs to adult DCs, neonatal DCs have 
altered cytokine responses after TLR stimulation. Reduced secre-
tion of the Th1- inducing cytokine IL- 12p70 (Figure 2), along with 
decreased IFNγ secretion,68 might underpin this. Upon stimulation 
with LPS, neonatal DCs also have attenuated expression of HLA- DR, 
CD86, CD80 and CD40 that might contribute to their reduced ca-
pacity to activate naïve cord blood T cells.69 Similarly, in murine neo-
natal models, DCs have been shown to efficiently migrate and be 
capable of antigen presentation but fail to upregulate co- stimulatory 
molecules in response to IFNγ.70
In human adults, metabolic rewiring supports DC activation. 
During differentiation from monocytes and from bone marrow 
progenitor cells, DCs use OXPHOS as the primary means of energy 
production.71 On activation, DCs switch to a glycolytic metabo-
lism and inhibition of glycolysis decreases surface expression of IL- 
12p70, MHC class I and class II as well as co- stimulatory CD40 and 
CD86.72 When looking at specific subsets of DCs, pDCs use both 
glycolysis and glutaminolysis fuelled OXPHOS to support activation 
with inhibition of these pathways resulting in decreased expression 
of HLA- DR, CD80, CD86 and IFNα.73,74 However, cDCs rely more 
exclusively on glycolysis which is crucial for CD40 and IL- 12 ex-
pression. In contrast to pDCs, TLR stimulation reduces OXPHOS in 
cDCs.74 Given the known down regulation of co- stimulatory mole-
cules and reduced cytokine production in neonatal DCs and their 
established link with metabolic reprogramming, investigation of 
underlying metabolic differences in neonates is warranted including 
comparison to other subsets, especially monocytes, to look for com-
mon denominators.
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2.7  |  Myeloid- derived suppressor cells
Myeloid- derived suppressor cells (MDSC) are a heterogeneous 
population of early myeloid- derived progenitor cells which share an 
immature state and the ability to suppress T- cell activation. While 
dichotomized into monocytic MDSC (M- MDSC) and granulocytic 
MDSC (G- MDSC) subsets, in humans these phenotypes are poorly 
established. However, general consensus defines these subsets as 
CD11b+ CD14+ HLA- DR- /low CD15- and CD11b+ CD14- CD15+, 
respectively.75 In adults, MDSC are typically associated with the pro- 
inflammatory environment of tumours and other chronic inflamma-
tory conditions. As such, MDSC have been studied primarily for their 
immune suppressive role in the tumour microenvironment where 
they potently suppress T- cell expansion and effector functions.
Recently in humans, the suppressive capacity of M- MDSC has 
been linked to specific metabolic adaptations. Compared with mono-
cytes, the dicarbonyl metabolite methylglyoxal is 30- fold higher in 
M- MDSC inhibiting glycolysis in these cells.76 M- MDSC also transfer 
cytoplasmic methylglyoxal to T cells in a contact- dependent man-
ner and inhibit T- cell metabolic reprogramming to suppress their 
expansion and effector functions.76 Methylglyoxal also selectively 
depletes L- arginine and L- glutamine,76 which are both amino acids 
required for T- cell function and might explain reports of depletion of 
L- arginine by MDSC.77 Other studies have demonstrated that fatty 
acid uptake and FAO mediated by STAT3/STAT5 and lipid uptake by 
CD36 are required for generation of highly suppressive MDSC in the 
tumour microenvironment.78,79
Compared with healthy adults, MDSC are transiently increased 
at birth with cord blood levels equivalent to those of cancer pa-
tients.80 MDSC frequency in neonates positively correlates with 
birth weight.81 MDSC from healthy weight neonates have greater 
suppressive capacity than those from very low weight neonates, 
potentially indicating a link between nutrient availability and MDSC 
function. Interestingly, breastmilk lactoferrin is key to generating 
M- MDSC and G- MDSC able to suppress neonatal T cells; however, 
the same effect is not observed in adult MDSC.80,82 Additionally, 
F I G U R E  2  Immune responses of neonates. Innate responses of neonates are characterized by attenuated responses and reduced pro- 
inflammatory phenotype with loss of some effector functions entirely. Adaptive responses are dominated by naïve cell subsets and generally 
less inflammatory responses, preferring the generation of regulatory cells. Created using biore nder.com
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lactoferrin treatment induced potent bacterial killing function in 
neonatal MDSC80 demonstrating potential roles beyond immune 
suppression. In mouse models of neonatal necrotizing enterocolitis, 
lactoferrin- treated MDSC are currently being investigated as a po-
tential therapeutic due to their ability to suppress T- cell activation 
and inflammation.80,81
3  |  ADAPTIVE IMMUNE RESPONSES
The adaptive immune system of neonates is commonly described as 
immature. While memory T- cell populations can be identified within 
the foetus, possibly arising from the foetal intestine,83,84 nearly all 
neonatal T and B lymphocytes display markers of antigen inexpe-
rienced naïve cells.17,83,84 Recent studies have also revealed the 
failure of human and mouse neonatal lymphocytes to differentiate 
into long- lived memory cells and their reduced secondary responses 
upon antigen re- exposure.85– 87
3.1  |  B cells
Neonatal B lymphocytes are almost exclusively antigen inexperi-
enced naïve B cells. Neonates have reduced class- switched antibody 
production, with almost no IgG or IgA antibody production on acti-
vation compared with adults which have been suggested to contrib-
ute to greater susceptibility to infection of neonates.88 Depending 
on the method of activation used, neonatal B cells exhibit both en-
hanced and reduced proliferation, leading researchers to conclude 
that while reduction in B- cell proliferation may be observed in some 
settings; neonatal B cells do not have a general defect in prolifera-
tion.88 However, survival of neonatal B cells across various subsets 
is decreased with most methods of activation. While much less is 
known about the immunometabolic features of B cells compared 
with other immune cells, we do know that unlike most other immune 
cells the upregulation of glycolysis does not appear to be crucial for 
their activation, proliferation or differentiation, despite increased 
import of glucose after activation.89 Rather, B cells appear to rely 
on OXPHOS to meet the demands of activation and proliferation, 
likely supported by glutaminolysis rather than glucose metabolism.89 
However, glucose does seem to be required for class switch recom-
bination which is known to be impaired in neonates.88,89 When 
assessing B- cell subsets for enzymes related to glycolytic and oxida-
tive metabolic pathways, naïve B cells were found to have the low-
est expression across all enzymes examined. Memory subsets had 
higher expression of metabolic enzymes while plasma cells had the 
highest expression of all enzymes.90 A recently identified subset of B 
cells, now termed regulatory B cells (Bregs), characterized as CD25hi 
CD38hi performs important regulatory functions, promoting tol-
erance during pregnancy.91 Bregs suppress the immune system 
through direct cell- to- cell signalling via CD80/CD86, IL- 10 and aden-
osine generation by the purine ecto- enzyme CD73. Bregs preferen-
tially downregulate IFNγ production along with the differentiation 
of Th1 and Th17 cells but not regulatory T cells (Tregs).92,93 Increased 
frequency of Bregs in cord blood has been suggested to play a role 
in the altered immune response of neonates, with their suppressive 
role postulated to be primarily through production of IL- 10 and co- 
stimulatory CD80/CD86 signalling to T cells.94,95 Adenosine produc-
tion is unlikely to be a mechanism used by neonatal Bregs for immune 
suppression as CD73 is markedly and selectively downregulated.96
Along with the observations summarized for other cell types 
above, impaired glycolysis might be a common mechanism of altered 
neonatal immune cell function although the upstream determinants 
of this might differ by cell type.
3.2  |  T cells
T cells are highly diverse and perform a multitude of specialized 
functions contributing to and orchestrating the immune response. 
Here, we will focus primarily on CD4+ (T helper), CD8+ (cytotoxic T 
cells) and CD4+FoxP3+ regulatory T cells.
3.2.1  |  CD4+ T helper cells
While the neonate is not devoid of memory CD4+ T cells, as already 
noted, neonatal CD4+ T cells are predominantly naïve (CD45RA+ 
CCR7+) and overwhelmingly display characteristics of recent thymic 
emigrants (RTEs) (Figure 2).97 Neonatal CD4+ T cells that do not re-
ceive signals from IL- 7 or other common γ chain cytokines are more 
susceptible to apoptosis leading to a high cell turnover rate.97,98 
IL- 7 promotes the survival and maturation of CD4+ RTEs without 
inducing differentiation,99 and this is supported by higher telomer-
ase expression in neonates, which prevents shortening of the tel-
omeres in this early stage of development.100 This high IL- 7- induced 
proliferative capacity is suggested to help maintain diversity in the 
T- cell repertoire 101 and, at least in mice, IL- 7- induced neonatal T- 
cell proliferation is linked to higher STAT5 activation, a signalling 
pathway shared with humans.102 The metabolic requirements to 
support rapid T- cell proliferation in neonates are unknown however, 
in adults aerobic glycolysis and OXPHOS drive proliferation and dif-
ferentiation of CD4+ T cells.103 We have shown a requirement for 
STAT5 signalling in very early adult naïve T- cell activation. Inhibiting 
STAT5 in naïve but not effector or central memory CD4+ T cells re-
sulted in reduced glutamine- dependent anaplerosis and loss of IL- 2 
production,104 highlighting the critical role of metabolic reprogram-
ming and the use of glutamine in the very earliest stages of T- cell 
activation in the periphery.
As mentioned earlier, CD4+ T- cell cytokine responses are 
considered to be Th2 skewed in neonates (Figure 2), in part due 
to altered functions of cells such as DCs. Additional to antigen- 
presenting cells influencing neonate T- cell phenotype through di-
minished IL- 12- p70 (as discussed previously), monocyte- derived 
pro- inflammatory cytokines have been shown to suppress IL- 2 pro-
duction inducing non- classic Th2 cells.46 However, characteristic 
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interleukin production of naïve CD4+ T cells also has been linked 
to epigenetic modification. Hypermethylation at CpG and non- CpG 
sites occurs within and adjacent to the IFNγ promoter region in neo-
natal naive CD4+ T cells and is accompanied by markedly reduced 
IFNγ production by neonates upon T- cell activation.105 Although re-
duced IFNγ production is widely reported in neonatal αβ T cells, it 
is, however, worth noting that neonatal γδ T cells do not exhibit the 
same defect.106
In mice, neonates are poised for a Th2 type response. They ex-
hibit pre- existing CpG hypomethylation at the CNS- 1 locus when 
resting and CpG methylation at the CNS- 1 locus remains lower 
than in adult mice after 5 days, under Th2- polarizing conditions.107 
In human neonates, the Th2 locus is extensively remodelled, with 
hypomethylation and permissive histone modifications selectively 
in Th2 cells cultured under Th2- polarizing conditions.108 A novel 
subset of neonatal naïve CD31+ CD4+ T cells storing an ungly-
cosylated isoform of IL- 4, not present in adults, has also been de-
scribed, however, any unique function of these cells has not yet been 
identified.109 The relative balance of cytokines has implications in 
early life programming of later immune function and allergic dis-
ease risk in particular.3 Greater expression of IL- 13 at birth, along 
with other epigenetic variations in metabolic genes such as RPTOR, 
PIK3D and MAPK1, has been linked with subsequent susceptibility 
to atopic disease in childhood.108,110 Reduced IFNγ at this time is a 
long- recognized hallmark of allergic disease risk.111 Therefore, there 
is much value in elucidating the immunometabolic regulation of T- 
cell effector cytokine production at this stage of development to 
provide mechanistic insight and therapeutic targets for mitigating 
non- communicable disease risk.
T- cell effector function has been linked closely with metabo-
lism in various studies16 and may have a role to play in skewed T- 
cell responses of neonates. Glycolysis is a specific requirement for 
IFNγ production in humans and in mice through post- transcriptional 
regulation by the glycolysis enzyme glyceraldehyde phosphate de-
hydrogenase (GAPDH).112– 114 In vitro and in vivo blockade of gly-
colysis is also known to reduce expression of the Th2 cytokines IL- 4 
and IL- 13 and whether GAPDH has a role to play here too is still 
unknown.115 Furthermore, TGFβ signalling significantly inhibits mi-
tochondrial complex V resulting in decreased ATP production and 
impaired IFNγ production in human CD4+ T cells.116 Some work 
has begun to explore how altered mitochondrial respiration in neo-
nates might contribute to altered T- cell activity. So far, mitochondrial 
mass of neonatal CD4+ T cells has been shown to be lower than 
adults and accompanied by reduced levels of ATP.117,118 However, 
on activation of T cells from preterm infants, higher calcium flux into 
the mitochondria than adults is observed along with increased ERK 
phosphorylation suggesting enhanced signalling for metabolic re-
programming.119 Finally, nutritional regulation of T- cell development 
has been shown in mice where oligosaccharide diets were found to 
have a role in regulating neonatal Th1 type responses in respiratory 
syncytial virus infection models.120 Such approaches might offer 
therapeutic strategies should immunometabolic signatures be found 
associated with disease outcomes.
3.2.2  |  CD8+ cytotoxic T cells
A number of features of neonatal CD8+ T cells have been associated 
with increased susceptibility of neonates to infection. CD8+ T- cell 
responses in neonates are described as innate- like, with reduced cy-
totoxic capability and increased expression of anti- microbial protein 
transcripts.121 Exploration of the epigenomic landscape has revealed 
changes associated with lower TCR signalling and cytotoxicity but 
higher expression of genes involved in cell cycle.121 In line with these 
findings, it is widely reported that neonatal CD8+ T cells are highly 
proliferative through homeostatic proliferation.100,122,123 This highly 
proliferative programme extends into activation.124 Neonatal CD8+ 
T cells divide more than their adult counterparts over the first three 
days of activation with the cells entering division sooner after ini-
tial activation and each division then happening faster in neonates. 
Differentiation, measured by CD62L and Ly6C expression, also oc-
curs faster in neonates (Figure 2) yet they become terminally differ-
entiated, shown by CD127 downregulation and KLRG1 upregulation, 
and fail to differentiate into long- lived memory cells (Figure 2), pro-
ducing weak CD8+ T- cell expansion on secondary challenge.124,125 
Rapid proliferation and differentiation in neonates are suggested to 
impair the development of memory CD8+ T cells.124 Studies in mice 
suggest a role for the inhibitor of let- 7 microRNA, lin28b, in main-
taining a neonate- like phenotype by CD8+ T cells (Figure 2).126
To support their highly proliferative phenotype, murine neona-
tal CD8+ T cells preferentially rely on glycolysis.85 Indeed, neonatal 
mice exhibit higher glycolytic metabolism than adults, a response 
attributable to functional programming by lin28b (Figure 2). High 
glycolytic metabolism was also linked directly to the inability of ne-
onates to form memory populations with pharmacological inhibition 
of glycolysis with 2DG able to restore formation of memory cells.85 
In comparison with mice, our understanding of human neonatal 
CD8+ T- cell metabolism is not as well developed and what little ev-
idence there is contrasts. For example, human umbilical cord blood 
CD8+ T cells have a propensity to differentiate into non- classical T 
cytotoxic (Tc)2 cells, when activated and this was associated with a 
decrease in glycolysis and an increase in fatty acid metabolism of Tc2 
cells.127 Much more work is needed to properly understand the role 
metabolism has to play in the fate of human neonatal CD8+ T cells.
3.2.3  |  Regulatory T cells
Regulatory T cells (Tregs) are crucial in preventing immune dysregu-
lation and promoting peripheral tolerance. The subset defined by 
expression of the transcription factor forkhead box (FOX)p3 will be 
the focus here. Tregs have emerged as critical to the success of preg-
nancy playing a vital role in maternal tolerance of the foetus and im-
munoregulation more generally at the foetal- maternal interface.128 
Furthermore, maternal factors such as allergy have been suggested 
to reduce Treg suppressive function in the offspring.129 IL- 2R- STAT5 
and TGFβ- SMAD signalling promote Treg differentiation through re-
cruitment to CNS2 and CNS1 of the FOXP3 locus, respectively.130,131 
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Tregs have high mitochondrial mass, relying on OXPHOS via mito-
chondrial oxidation of pyruvate and lipids upon activation, unlike 
conventional T cells that primarily rely on aerobic glycolysis.132,133 
While proliferation of Tregs is fuelled primarily through OXPHOS, 
glycolysis appears to be crucial to the suppressor function of Tregs. 
Enolase- 1, a glycolytic enzyme, functions as a regulator of conserved 
non- coding sequence (CNS)2, preventing the transcription of a 
FOXP3 splice isoform containing exon- 2 (FOXP3- E2).134 Exogenous 
metabolites might also affect the stability of Tregs. Tregs have in-
creased cell surface expression of ecto- nucleotidases CD39 and 
CD73, which convert ATP into immunosuppressive adenosine.135 
In neonatal T cells, CD39 expression is highest in activated Tregs, 
demonstrating the importance of their immunomodulatory func-
tion; the frequency of this population of Tregs correlates inversely 
with clinical severity of sepsis in neonates.136 Intriguingly, neonatal 
CD4+FOXP3- T cells display a natural propensity to differentiate 
into Tregs98 (Figure 2) likely reflecting suboptimal stimulation via 
TCR.137 Given the role metabolism has in determining T- cell fate, an 
intrinsic metabolic programme in naïve neonatal CD4+ cells linked 
to early post- TCR activation events might favour the preferential 
generation of Tregs contributing to the development of immune tol-
erance at this time.
3.3  |  Outlook
Immunometabolism is now a well- established field enabling signifi-
cant advances in our understanding of human immune cell fate and 
function. However, to date, little progress has been made in apply-
ing this to the understanding of human neonatal immune responses. 
Some initial work is revealing fundamental differences in cellular me-
tabolism likely underpinning well- described phenotypic and func-
tional differences across the life course. However, caution must be 
taken when the focus remains on umbilical cord blood collected at 
the transition from intrauterine to extrauterine life and the changes 
in fuel demand and provision that occur around this time. We also 
must be mindful that neonates do not simply lack in comparison with 
adults and alternative fuel substrates (e.g. ketone bodies as above) 
and higher levels of exogenous metabolites (e.g. adenosine as above) 
might drive unique phenotypes at this stage of development. Much 
more work is needed especially extending observations beyond um-
bilical cord blood to samples collected in the days, weeks and months 
after birth. Such work is limited by sample volumes and will need to 
focus on single- cell functional genomic approaches linking transcrip-
tional and translational regulation of the mechanisms at play accom-
panying these with emerging flow cytometry- based approaches to 
the study of immunometabolism such as SCENITH.138 Future work 
should establish the metabolic underpinnings of neonatal immune 
cell function and explore how the unique energy demands, immune 
requirements and rapid development of neonates have led to this 
highly evolved, age- appropriate phenotype. Understanding immu-
nometabolism in neonates is an exciting field of research potentially 
harbouring new ways of combatting many diseases by providing un-
tapped insight into diverse functional roles of the immune system.
IRB STATEMENT
All of our work involving samples from human participants is re-
viewed and approved by a Health Research Authority or University 
research ethics committee with samples and data collected with in-
formed consent of the donor.
ACKNOWLEDG EMENTS
The authors would like to thank Swansea Bay University Health 
Board for their long- standing and ongoing support of our research 
endeavours.
CONFLIC T OF INTERE S T
None to declare.
AUTHOR CONTRIBUTION
Sean R Holm: Writing- original draft (lead). Benjamin James Jenkins: 
Writing- original draft (supporting); Writing- review & editing (sup-
porting). April Rees: Writing- review & editing (supporting). James 
G Cronin: Supervision (supporting); Writing- review & editing (sup-
porting). Nicholas Jones: Supervision (supporting); Writing- review 
& editing (supporting). Catherine A Thornton: Supervision (lead); 
Writing- original draft (supporting); Writing- review & editing (lead).
PEER RE VIE W
The peer review history for this article is available at https://publo 
ns.com/publo n/10.1111/pai.13583.
ORCID
Catherine A. Thornton  https://orcid.org/0000-0002-5153-573X 
R E FE R E N C E S
 1. Herberth G, Hinz D, Bauer M, et al. Environmental exposure during 
pregnancy modulates fetal Treg development with consequences 
for the allergy risk of the child. J Reprod Immunol. 2012;94(1):54. 
https://doi.org/10.1016/j.jri.2012.03.336
 2. Grieger JA, Clifton VL, Tuck AR, Wooldridge AL, Robertson SA, 
Gatford KL. In utero programming of allergic susceptibility. Int Arch 
Allergy Imm. 2016;169(2):80- 92. https://doi.org/10.1159/00044 
3961
 3. Campbell DE, Boyle RJ, Thornton CA, Prescott SL. Mechanisms 
of allergic disease— environmental and genetic determinants for 
the development of allergy. Clin Exp Allergy. 2015;45(5):844- 858. 
https://doi.org/10.1111/cea.12531
 4. Sattler S, Rosenthal N. The neonate versus adult mammalian 
immune system in cardiac repair and regeneration. BBA- Mol 
Cell Res. 2016;1863(7):1813- 1821. https://doi.org/10.1016/j.
bbamcr.2016.01.011
 5. Kan B, Michalski C, Fu H, et al. Cellular metabolism con-
strains innate immune responses in early human ontogeny. Nat 
Commun. 2018;9(1):94822. https://doi.org/10.1038/s4146 7- 018- 
07215 - 9
10  |    HOLM et aL.
 6. Saito S. Cytokine network at the feto- maternal interface. J Reprod 
Immunol. 2000;47(2):87- 103. https://doi.org/10.1016/s0165 - 0378 
(00)00060 - 7
 7. Levy O, Coughlin M, Cronstein BN, Roy RM, Desai A, Wessels MR. 
The adenosine system selectively inhibits TLR- mediated TNF- alpha 
production in the human newborn. J Immunol. 2006;177(3):1956- 
1966. https://doi.org/10.4049/jimmu nol.177.3.1956
 8. Saghafian- Hedengren S, Holmlund U, Amoudruz P, Nilsson C, 
Sverremark- Ekstrom E. Maternal allergy influences p38- mitogen- 
activated protein kinase activity upon microbial challenge in CD14(+) 
monocytes from 2- year- old children. Clin Exp Allergy. 2008;38(3):449- 
457. https://doi.org/10.1111/j.1365- 2222. 2007.02917.x
 9. Palmer AC. Nutritionally mediated programming of the devel-
oping immune system. Adv Nutr. 2011;2(5):377- 395. https://doi.
org/10.3945/an.111.000570
 10. Shew SB, Jaksic T. The metabolic needs of critically ill children and 
neonates. Semin Pediat Surg. 1999;8(3):131- 139.
 11. Butte NF. Energy requirements of infants. Public Health Nutr. 
2005;8(7A):953- 967. https://doi.org/10.1079/phn20 05790
 12. Brook B, Harbeson D, Ben- Othman R, Viemann D, Kollmann TR. 
Newborn susceptibility to infection vs. disease depends on com-
plex in vivo interactions of host and pathogen. Semin Immunopathol. 
2017;39(6):615- 625. https://doi.org/10.1007/s002 8 1- 017 - 0651- z
 13. Harbeson D, Francis F, Bao W, Amenyogbe NA, Kollmann TR. 
Energy demands of early life drive a disease tolerant phenotype 
and dictate outcome in neonatal bacterial sepsis. Front Immunol. 
2018;9:91918. https://doi.org/10.3389/fimmu.2018.01918
 14. Harbeson D, Ben- Othman R, Amenyogbe N, Kollmann TR. 
Outgrowing the immaturity myth: the cost of defending from neo-
natal infectious disease. Front Immunol. 2018;91077. https://doi.
org/10.3389/fimmu.2018.01077
 15. O'Neill LAJ, Kishton RJ, Rathmell J. A guide to immunometabolism 
for immunologists. Nat Rev Immunol. 2016;16(9):553- 565. https://
doi.org/10.1038/nri.2016.70
 16. Geltink RIK, Kyle RL, Pearce EL. Unraveling the complex inter-
play between T cell metabolism and function. Annu Rev Immunol. 
2018;36(36):461- 488. https://doi.org/10.1146/annur ev- immun ol- 
04261 7- 053019
 17. Basha S, Surendran N, Pichichero M. Immune responses in neo-
nates. Expert Rev Clin Immuy. 2014;10(9):1171- 1184. https://doi.
org/10.1586/17446 66x.2014.942288
 18. Carr R, Huizinga TWJ, Kleijer M, Davies JM. Changes in plasma 
FcRIII demonstrate increasing receptor production during late 
pregnancy and after preterm birth. Pediatr Res. 1992;32(5):505- 
508. https://doi.org/10.1203/00006 450- 19921 1000- 00001
 19. Kim SK, Keeney SE, Alpard SK, Schmalstieg FC. Comparison of L- 
selectin and CD11b on neutrophils of adults and neonates during 
the first month of life. Pediatr Res. 2003;53(1):132- 136. https://doi.
org/10.1203/01.pdr.00000 41515.78650.11
 20. Raymond SL, Hawkins RB, Murphy TJ, et al. Impact of toll- like 
receptor 4 stimulation on human neonatal neutrophil sponta-
neous migration, transcriptomics, and cytokine production. J 
Mol Med. 2018;96(7):673- 684. https://doi.org/10.1007/s0010 
9- 018- 1646- 5
 21. Al- Hertani W, Yan SR, Byers DM, Bortolussi R. Human new-
born polymorphonuclear neutrophils exhibit decreased levels of 
MyD88 and attenuated p38 phosphorylation in response to lipo-
polysaccharide. Clin Invest Med. 2007;30(2):E44- E53.
 22. Yost CC, Cody MJ, Harris ES, et al. Impaired neutrophil extracel-
lular trap (NET) formation: a novel innate immune deficiency of 
human neonates. Blood. 2009;113(25):6419- 6427. https://doi.
org/10.1182/blood - 2008- 07- 171629
 23. Rodriguez- Espinosa O, Rojas- Espinosa O, Moreno- Altamirano MMB, 
Lopez- Villegas EO, Sanchez- Garcia FJ. Metabolic requirements for 
neutrophil extracellular traps formation. Immunology. 2015;145(2):213- 
224. https://doi.org/10.1111/imm.12437.
 24. Borregaard N, Herlin T. Energy- metabolism of human- neutrophils 
during phagocytosis. J Clin Invest. 1982;70(3):550- 557. https://doi.
org/10.1172/jci11 0647
 25. Awasthi D, Nagarkoti S, Sadaf S, Chandra T, Kumar S, Dikshit M. 
Glycolysis dependent lactate formation in neutrophils: a metabolic 
link between NOX- dependent and independent NETosis. BBA- 
Mol Basis Dis. 2019;1865(12):165542. https://doi.org/10.1016/j.
bbadis.2019.165542
 26. Bougneres PF, Lemmel C, Ferre P, Bier DM. Ketone- body trans-
port in the human neonate and infant. J Clin Invest. 1986;77(1):42- 
48. https://doi.org/10.1172/jci11 2299
 27. Grinberg N, Elazar S, Rosenshine I, Shpigel NY. Beta- 
hydroxybutyrate abrogates formation of bovine neutrophil 
extracellular traps and bactericidal activity against mammary 
pathogenic Escherichia coli. Infect Immun. 2008;76(6):2802- 2807. 
https://doi.org/10.1128/iai.00051 - 08.
 28. Juul SE, Haynes JW, McPherson RJ. Evaluation of eosinophilia 
in hospitalized preterm infants. J Perinatol. 2005;25(3):182- 188. 
https://doi.org/10.1038/sj.jp.7211226
 29. Porter L, Toepfner N, Bashant KR, et al. Metabolic profiling of 
human eosinophils. Front Immunol. 2018;9:91404. https://doi.
org/10.3389/fimmu.2018.01404
 30. Jones N, Vincent EE, Felix LC, et al. Interleukin- 5 drives glycolysis 
and reactive oxygen species- dependent citric acid cycling by eo-
sinophils. Allergy. 2020;75(6):1361- 1370. https://doi.org/10.1111/
all.14158
 31. Steer CA, Martinez- Gonzalez I, Ghaedi M, Allinger P, Matha L, 
Takei F. Group 2 innate lymphoid cell activation in the neonatal 
lung drives type 2 immunity and allergen sensitization. J Allergy 
Clin Immunol. 2017;140(2):593- 595.e3. https://doi.org/10.1016/j.
jaci.2016.12.984
 32. Bennstein SB, Scherenschlich N, Weinhold S, et al. Transcriptional 
and functional characterization of neonatal circulating ILCs. Stem 
Cells Transl Med. 2021;10(6):867- 882. https://doi.org/10.1002/
sctm.20- 0300
 33. Steer CA, Matha L, Shim H, Takei F. Lung group 2 innate lymphoid cells 
are trained by endogenous IL- 33 in the neonatal period. JCI Insight. 
2020;5(14)e135961. https://doi.org/10.1172/jci.insig ht.135961
 34. Cheon IS, Son YM, Jiang LI, et al. Neonatal hyperoxia promotes 
asthma- like features through IL- 33- dependent ILC2 responses. 
J Allergy Clin Immunol. 2018;142(4):1100- 1112. https://doi.
org/10.1016/j.jaci.2017.11.025
 35. Monticelli LA, Buck MD, Flamar AL, et al. Arginase 1 is an innate 
lymphoid- cell- intrinsic metabolic checkpoint controlling type 
2 inflammation. Nat Immunol. 2016;17(6):656- 665. https://doi.
org/10.1038/ni.3421
 36. Helou DG, Shafiei- Jahani P, Lo R, et al. PD- 1 pathway regulates 
ILC2 metabolism and PD- 1 agonist treatment ameliorates air-
way hyperreactivity. Nat Commun. 2020;11(1):3398. https://doi.
org/10.1038/s4146 7- 020- 17813 - 1
 37. Wilhelm C, Harrison OJ, Schmitt V, et al. Critical role of fatty acid 
metabolism in ILC2- mediated barrier protection during malnutri-
tion and helminth infection. J Exp Med. 2016;213(8):1409- 1418. 
https://doi.org/10.1084/jem.20151448
 38. Levy O, Zarember KA, Roy RM, Cywes C, Godowski PJ, Wessels MR. 
Selective impairment of TLR- mediated innate immunity in human 
newborns: neonatal blood plasma reduces monocyte TNF- alpha in-
duction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, 
but preserves the response to R- 848. J Immunol. 2004;173(7):4627- 
4634. https://doi.org/10.4049/jimmu nol.173.7.4627
 39. Han P, McDonald T, Hodge G. Potential immaturity of the T- cell and antigen- 
presenting cell interaction in cord blood with particular emphasis on the 
CD40- CD40 ligand costimulatory pathway. Immunology. 2004;113(1):26- 
34. https://doi.org/10.1111/j.1365- 2567.2004.01933.x
 40. Hegge I, Niepel F, Lange A, Vogelgesang A, Heckmann M, Ruhnau J. 
Functional analysis of granulocyte and monocyte subpopulations 
    |  11HOLM et aL.
in neonates. Mol Cell Pediatr. 2019;6(1):5. https://doi.org/10.1186/
s4034 8- 019- 0092- y
 41. Hikita N, Cho Y, Tachibana D, Hamazaki T, Koyama M, Tokuhara 
D. Cell surface antigens of neonatal monocytes are selectively im-
paired in basal expression, but hyperresponsive to lipopolysaccha-
ride and zymosan. J Reprod Immunol. 2019;136:102614. https://
doi.org/10.1016/j.jri.2019.102614
 42. Smith CL, Dickinson P, Forster T, et al. Identification of a human 
neonatal immune- metabolic network associated with bacterial 
infection. Nat Commun. 2014;5(1):5649. https://doi.org/10.1038/
ncomm s5649
 43. Dreschers S, Ohl K, Lehrke M, et al. Impaired cellular energy me-
tabolism in cord blood macrophages contributes to abortive re-
sponse toward inflammatory threats. Nat Commun. 2019;101685. 
https://doi.org/10.1038/s4146 7- 019- 09359 - 8
 44. Dreschers S, Ohl K, Schulte N, Tenbrock K, Orlikowsky TW. 
Impaired functional capacity of polarised neonatal macrophages. 
Sci Rep. 2020;10(1)624. https://doi.org/10.1038/s4159 8- 019- 
56928 - 4
 45. Covarrubias AJ, Aksoylar HI, Horng T. Control of macrophage me-
tabolism and activation by mTOR and Akt signaling. Semin Immunol. 
2015;27(4):286- 296. https://doi.org/10.1016/j.smim.2015. 08.001
 46. Zhang YX, Collier F, Naselli G, et al. Cord blood monocyte- derived 
inflammatory cytokines suppress IL- 2 and induce nonclassic 
"T(H)2- type" immunity associated with development of food al-
lergy. Sci Transl Med. 2016;8(321):321ra8. https://doi.org/10.1126/
scitr anslm ed.aad4322
 47. Prescott SL, Noakes P, Chow BWY, et al. Presymptomatic dif-
ferences in toll- like receptor function in infants who have al-
lergy. J Allergy Clin Immunol. 2008;122(2):391- 399. https://doi.
org/10.1016/j.jaci.2008.04.042
 48. Tulic MK, Hodder M, Forsberg A, et al. Differences in innate immune 
function between allergic and nonallergic children: New insights 
into immune ontogeny. J Allergy Clin Immunol. 2011;127(2):470- 
478.e1. https://doi.org/10.1016/j.jaci.2010.09.020
 49. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of 
natural killer cells. Nature Immunol. 2008;9(5):503- 510. https://doi.
org/10.1038/ni1582
 50. Shereck E, Day NS, Awasthi A, et al. Immunophenotypic, cytotoxic, 
proteomic and genomic characterization of human cord blood vs. pe-
ripheral blood CD56(Dim) NK cells. Innate Immunity. 2019;25(5):294- 
304. https://doi.org/10.1177/17534 25919 846584
 51. Strauss- Albee DM, Liang EC, Ranganath T, Aziz N, Blish CA. The 
newborn human NK cell repertoire is phenotypically formed but 
functionally reduced. Cytometry Part B. 2017;92(1):33- 41. https://
doi.org/10.1002/cyto.b.21485
 52. Luevano M, Daryouzeh M, Alnabhan R, et al. The unique profile of cord 
blood natural killer cells balances incomplete maturation and effec-
tive killing function upon activation. Hum Immunol. 2012;73(3):248- 
257. https://doi.org/10.1016/j.humimm.2011.12.015
 53. Sundstrom Y, Nilsson C, Lilja G, Karre K, Troye- Blomberg M, 
Berg L. The expression of human natural killer cell receptors in 
early life. Scand J Immunol. 2007;66(2– 3):335- 344. https://doi.
org/10.1111/j.1365- 3083.2007.01980.x
 54. Keppel MP, Saucier N, Mah AY, Vogel TP, Cooper MA. Activation- 
specific metabolic requirements for NK cell IFN- gamma produc-
tion. J Immunol. 2015;194(4):1954- 1962. https://doi.org/10.4049/
jimmu nol.1402099
 55. Velasquez SY, Himmelhan BS, Kassner N, et al. Innate cyto-
kine induced early release of IFN gamma and CC chemokines 
from hypoxic human NK cells is independent of glucose. Cells. 
2020;9(3)734. https://doi.org/10.3390/cells 9030734
 56. Keating SE, Zaiatz- Bittencourt V, Loftus RM, et al. Metabolic repro-
gramming supports IFN- gamma production by CD56(bright) NK 
cells. J Immunol. 2016;196(6):2552- 2560. https://doi.org/10.4049/
jimmu nol.1501783
 57. Jensen H, Potempa M, Gotthardt D, Lanier LL. Cutting edge: IL- 
2- induced expression of the amino acid transporters SLC1A5 
and CD98 is a prerequisite for NKG2D- mediated activation of 
human NK cells. J Immunol. 2017;199(6):1967- 1972. https://doi.
org/10.4049/jimmu nol.1700497
 58. Wang ZX, Guan D, Wang S, Chai LYA, Xu SL, Lam KP. Glycolysis 
and oxidative phosphorylation play critical roles in natural killer 
cell receptor- mediated natural killer cell functions. Front Immunol. 
2020;11202. https://doi.org/10.3389/fimmu.2020.00202
 59. Donnelly RP, Loftus RM, Keating SE, et al. mTORC1- Dependent 
metabolic reprogramming is a prerequisite for NK cell effec-
tor function. J Immunol. 2014;193(9):4477- 4484. https://doi.
org/10.4049/jimmu nol.1401558
 60. Singh M, Orazulike NC, Ashmore J, Konje JC. Changes in mater-
nal serum transforming growth factor beta- 1 during pregnancy: a 
cross- sectional study. Biomed Res Int. 2013;2013:1– 5. https://doi.
org/10.1155/2013/318464
 61. Frost BL, Jilling T, Lapin B, Maheshwari A, Caplan MS. Maternal 
breast milk transforming growth factor- beta and feeding intoler-
ance in preterm infants. Pediatr Res. 2014;76(4):386- 393. https://
doi.org/10.1038/pr.2014.96
 62. Power LL, Popplewell EJ, Holloway JA, Diaper ND, Warner 
JO, Jones CA. Immunoregulatory molecules during pregnancy 
and at birth. J Reprod Immunol. 2002;56(1- 2):19- 28. https://doi.
org/10.1016/S0165 - 0378(01)00146 - 2
 63. Trotta R, Dal Col J, Yu JH, et al. TGF- beta utilizes SMAD3 to inhibit 
CD16- mediated IFN- gamma production and antibody- dependent 
cellular cytotoxicity in human NK cells. J Immunol. 2008;181(6):3784- 
3792. https://doi.org/10.4049/jimmu nol.181.6. 3784
 64. Wilson EB, El- Jawhari JJ, Neilson AL, et al. Human tumour immune 
evasion via TGF- beta blocks NK cell activation but not survival al-
lowing therapeutic restoration of anti- tumour activity. PLoS ONE. 
2011;6(9)e22842. https://doi.org/10.1371/journ al.pone.0022842
 65. Viel S, Marcais A, Guimaraes FSF, et al. TGF- beta inhibits the activa-
tion and functions of NK cells by repressing the mTOR pathway. Sci 
Signal. 2016;9(415)ra19. https://doi.org/10.1126/scisi gnal.aad1884
 66. Zaiatz- Bittencourt V, Finlay DK, Gardiner CM. Canonical TGF- 
beta signaling pathway represses human NK cell metabolism. J 
Immunol. 2018;200(12):3934- 3941. https://doi.org/10.4049/jimmu 
nol.1701461
 67. Borras FE, Matthews NC, Lowdell MW, Navarrete CV. Identification 
of both myeloid CD11c(+) and lymphoid CD11c(- ) dendritic cell 
subsets in cord blood. Br J Haematol. 2001;113(4):925- 931. 
https://doi.org/10.1046/j.1365- 2141.2001.02840.x
 68. Langrish CL, Buddle JC, Thrasher AJ, Goldblatt D. Neonatal 
dendritic cells are intrinsically biased against Th- 1 immune re-
sponses. Clin Exp Immunol. 2002;128(1):118- 123. https://doi.
org/10.1046/j.1365- 2249.2002.01817.x
 69. De Wit D, Tonon S, Olislagers V, et al. Impaired responses to toll- 
like receptor 4 and toll- like receptor 3 ligands in human cord blood. 
J Autoimmun. 2003;21(3):277- 281. https://doi.org/10.1016/j.
jaut.2003.08.003
 70. Lau- Kilby AW, Turfkruyer M, Kehl M, et al. Type I IFN ineffectively 
activates neonatal dendritic cells limiting respiratory antiviral T- 
cell responses. Mucosal Immunol. 2020;13(2):371- 380. https://doi.
org/10.1038/s4138 5- 019- 0234- 5
 71. Wculek SK, Khouili SC, Priego E, Heras- Murillo I, Sancho D. 
Metabolic control of dendritic cell functions: digesting informa-
tion. Front Immunol. 2019;10:10775. https://doi.org/10.3389/
fimmu.2019.00775
 72. Everts B, Amiel E, Huang SCC, et al. TLR- driven early glycolytic 
reprogramming via the kinases TBK1- IKK epsilon supports the 
anabolic demands of dendritic cell activation. Nature Immunol. 
2014;15(4):323. https://doi.org/10.1038/ni.2833
 73. Bajwa G, DeBerardinis RJ, Shao B, Hall B, Farrar JD, Gill MA. 
Cutting edge: critical role of glycolysis in human plasmacytoid 
12  |    HOLM et aL.
dendritic cell antiviral responses. J Immunol. 2016;196(5):2004- 
2009. https://doi.org/10.4049/jimmu nol.1501557
 74. Basit F, Mathan T, Sancho D, de Vries IJM. Human dendritic cell 
subsets undergo distinct metabolic reprogramming for immune 
response. Front Immunol. 2018;9:92489. https://doi.org/10.3389/
fimmu.2018.02489
 75. Sica A, Strauss L. Energy metabolism drives myeloid- derived sup-
pressor cell differentiation and functions in pathology. J Leuk Biol. 
2017;102(2):325- 334. https://doi.org/10.1189/jlb.4MR11 16- 476R
 76. Baumann T, Dunkel A, Schmid C, et al. Regulatory myeloid cells 
paralyze T cells through cell- cell transfer of the metabolite 
methylglyoxal. Nat Immunol. 2020;21(5):555- 566. https://doi.
org/10.1038/s4159 0- 020- 0666- 9
 77. Rodriguez PC, Ochoa AC. Arginine regulation by myeloid derived 
suppressor cells and tolerance in cancer: mechanisms and thera-
peutic perspectives. Immunol Rev. 2008;222:180- 191. https://doi.
org/10.1111/j.1600- 065X.2008.00608.x
 78. Hossain F, Al- Khami AA, Wyczechowska D, et al. Inhibition of 
fatty acid oxidation modulates immunosuppressive functions 
of myeloid- derived suppressor cells and enhances cancer ther-
apies. Cancer Immunol Res. 2015;3(11):1236- 1247. https://doi.
org/10.1158/2326- 6066.cir- 15- 0036
 79. Al- Khami AA, Zheng L, Del Valle L, et al. Exogenous lipid uptake induces 
metabolic and functional reprogramming of tumor- associated myeloid- 
derived suppressor cells. Oncoimmunology. 2017;6(10):e1344804. 
https://doi.org/10.1080/21624 02x.2017.1344804
 80. Gervassi A, Lejarcegui N, Dross S, et al. Myeloid derived suppres-
sor cells are present at high frequency in neonates and suppress in 
vitro T cell responses. PLoS ONE. 2014;9(9):e107816. https://doi.
org/10.1371/journ al.pone.0107816
 81. Liu Y, Perego M, Xiao Q, et al. Lactoferrin- induced myeloid- derived 
suppressor cell therapy attenuates pathologic inflammatory con-
ditions in newborn mice. J Clin Invest. 2019;129(10):4261- 4275. 
https://doi.org/10.1172/jci12 8164
 82. He YM, Li X, Perego M, et al. Transitory presence of myeloid- 
derived suppressor cells in neonates is critical for control of inflam-
mation. Nat Med. 2018;24(2):224- 231. https://doi.org/10.1038/
nm.4467
 83. Zhang X, Mozeleski B, Lemoine S, et al. CD4 T cells with effector 
memory phenotype and function develop in the sterile environ-
ment of the fetus. Sci Transl Med. 2014;6(238):238ra72. https://
doi.org/10.1126/scitr anslm ed.3008748
 84. Li NA, van Unen V, Abdelaal T, et al. Memory CD4(+) T cells are gen-
erated in the human fetal intestine. Nat Immunol. 2019;20(3):301- 
312. https://doi.org/10.1038/s4159 0- 018- 0294- 9
 85. Tabilas C, Wang J, Liu XJ, Locasale JW, Smith NL, Rudd BD. Cutting 
edge: elevated glycolytic metabolism limits the formation of mem-
ory CD8(+) T cells in early life. J Immunol. 2019;203(10):2571- 2576. 
https://doi.org/10.4049/jimmu nol.1900426
 86. Cossarizza A, Ortolani C, Paganelli R, et al. CD45 isoforms expression on 
CD4(+) and CD8(+) T cells throughout life, from newborns to centenari-
ans: implications for T cell memory. Mech Ageing Dev. 1996;86(3):173- 
195. https://doi.org/10.1016/0047- 6374(95)01691 - 0
 87. Morbach H, Eichhorn EM, Liese JG, Girschick HJ. Reference 
values for B cell subpopulations from infancy to adult-
hood. Clin Exp Immunol. 2010;162(2):271- 279. https://doi.
org/10.1111/j.1365- 2249.2010.04206.x
 88. Glaesener S, Jaenke C, Habener A, et al. Decreased production of 
class- switched antibodies in neonatal B cells is associated with in-
creased expression of miR- 181b. PLoS ONE. 2018;13(2):e0192230. 
https://doi.org/10.1371/journ al.pone.0192230
 89. Waters LR, Ahsan FM, Wolf DM, Shirihai O, Teitell MA. Initial B cell 
activation induces metabolic reprogramming and mitochondrial 
remodeling. iScience. 2018;5:99- 109. https://doi.org/10.1016/j.
isci.2018.07.005
 90. Glass DR, Tsai AG, Oliveria JP, et al. An integrated multi- omic 
single- cell atlas of human B cell identity. Immunity. 2020;53(1):217- 
232.e5. https://doi.org/10.1016/j.immuni.2020.06.013
 91. Lima J, Martins C, Leandro MJ, et al. Characterization of B cells 
in healthy pregnant women from late pregnancy to post- partum: 
a prospective observational study. BMC Pregnancy Childbirth. 
2016;16(1):16139. https://doi.org/10.1186/s1288 4- 016- 0927- 7
 92. Blair PA, Noreña LY, Flores- Borja F, et al. CD19(+)CD24(hi)
CD38(hi) B cells exhibit regulatory capacity in healthy individuals 
but are functionally impaired in systemic lupus erythematosus pa-
tients. Immunity. 2010;32(1):129- 140. https://doi.org/10.1016/j.
immuni.2009.11.009
 93. Flores- Borja F, Bosma A, Ng D, et al. CD19(+)CD24(hi)CD38(hi) B 
cells maintain regulatory T cells while limiting T(H)1 and T(H)17 
differentiation. Sci Transl Med. 2013;5(173):173ra23. https://doi.
org/10.1126/scitr anslm ed.3005407
 94. Esteve- Solé A, Teixidó I, Deyà- Martínez A, et al. Characterization 
of the highly prevalent regulatory CD24(hi)CD38(hi) B- cell popula-
tion in human cord blood. Front Immunol. 2017;8:201. https://doi.
org/10.3389/fimmu.2017.00201
 95. Sarvaria A, Basar R, Mehta RS, et al. IL- 10(+) regulatory B cells are 
enriched in cord blood and may protect against cGVHD after cord 
blood transplantation. Blood. 2016;128(10):1346- 1361. https://
doi.org/10.1182/blood - 2016- 01- 695122
 96. Pettengill MA, Levy O. Circulating human neonatal naive B cells 
are deficient in CD73 Impairing purine salvage. Front Immunol. 
2016;7:121. https://doi.org/10.3389/fimmu.2016.00121
 97. Hassan J, Reen DJ. Human recent thymic emigrants- identification, ex-
pansion, and survival characteristics. J Immunol. 2001;167(4):1970- 
1976. https://doi.org/10.4049/jimmu nol.167. 4.1970
 98. Thornton CA, Upham JW, Wikstrom ME, et al. Functional mat-
uration of CD4(+)CD25(+)CTLA4(+)CD45RA(+) T regulatory 
cells in human neonatal T cell responses to environmental anti-
gens/allergens. J Immunol. 2004;173(5):3084- 3092. https://doi.
org/10.4049/jimmu nol.173.5.3084
 99. Soares MVD, Borthwick NJ, Maini MK, Janossy G, Salmon M, 
Akbar AN. IL- 7- dependent extrathymic expansion of CD45RA(+) 
T cells enables preservation of a naive repertoire. J Immunol. 
1998;161(11):5909- 5917.
 100. Schönland SO, Zimmer JK, Lopez- Benitez CM, et al. Homeostatic 
control of T- cell generation in neonates. Blood. 2003;102(4):1428- 
1434. https://doi.org/10.1182/blood - 2002- 11- 3591
 101. Hassan J, Reen DJ. IL- 7 promotes the survival and maturation 
but not differentiation of human post- thymic CD4(+) T cells. Eur J 
Immunol. 1998;28(10):3057- 3065.
 102. Opiela SJ, Koru- Sengul T, Adkins B. Murine neonatal recent thymic 
emigrants are phenotypically and functionally distinct from adult 
recent thymic emigrants. Blood. 2009;113(22):5635- 5643. https://
doi.org/10.1182/blood - 2008- 08- 173658
 103. Macintyre AN, Gerriets VA, Nichols AG, et al. The glucose trans-
porter Glut1 is selectively essential for CD4 T cell activation 
and effector function. Cell Metab. 2014;20(1):61- 72. https://doi.
org/10.1016/j.cmet.2014.05.004
 104. Jones N, Vincent EE, Cronin JG, et al. Akt and STAT5 mediate naive 
human CD4+T- cell early metabolic response to TCR stimulation. 
Nat Commun. 2019;102042. https://doi.org/10.1038/s4146 7- 019- 
10023 - 4
 105. White GP, Watt PM, Holt BJ, Holt PG. Differential patterns of 
methylation of the IFN- gamma promoter at CpG and Non- CpG 
sites underlie differences in IFN- gamma gene expression be-
tween human neonatal and adult CD45RO(- ) T cells. J Immunol. 
2002;168(6):2820- 2827. https://doi.org/10.4049/jimmu nol.168. 
6.2820
 106. Gibbons DL, Haque SFY, Silberzahn T, et al. Neonates harbour 
highly active gamma delta T cells with selective impairments in 
    |  13HOLM et aL.
preterm infants. Eur J Immunol. 2009;39(7):1794- 1806. https://doi.
org/10.1002/eji.20093 9222
 107. Rose S, Lichtenheld M, Foote MR, Adkins B. Murine neonatal 
CD4(+) cells are poised for rapid Th2 effector- like function. J 
Immunol. 2007;178(5):2667- 2678. https://doi.org/10.4049/jimmu 
nol.178.5.2667
 108. Webster RB, Rodriguez Y, Klimecki WT, Vercelli D. The human IL- 13 
locus in neonatal CD4(+) T cells is refractory to the acquisition of 
a repressive chromatin architecture. J Biol Chem. 2007;282(1):700- 
709. https://doi.org/10.1074/jbc.M6095 01200
 109. Hebel K, Weinert S, Kuropka B, et al. CD4(+) T cells from human 
neonates and infants are poised spontaneously to run a nonclassi-
cal IL- 4 program. J Immunol. 2014;192(11):5160- 5170. https://doi.
org/10.4049/jimmu nol.1302539
 110. Martino D, Neeland M, Dang T, et al. Epigenetic dysregulation of naive 
CD4+T- cell activation genes in childhood food allergy. Nat Commun. 
2018;9:3308. https://doi.org/10.1038/s4146 7- 018- 05608 - 4
 111. Tang MLK, Kemp AS, Thorburn J, Hill DJ. Reduced interferon- 
gamma secretion in neonates and subsequent atopy. Lancet. 
1994;344(8928):983- 985. https://doi.org/10.1016/s0140 - 6736 
(94)91641 - 1
 112. Jones N, Cronin JG, Dolton G, et al. Metabolic adaptation of 
human CD4(+) and CD8(+) T- cells to T- cell receptor- mediated 
stimulation. Front Immunol. 2017;8:1516. https://doi.org/10.3389/
fimmu.2017.01516
 113. Chang C- H, Curtis J, Maggi L, et al. Posttranscriptional control of T 
cell effector function by aerobic glycolysis. Cell. 2013;153(6):1239- 
1251. https://doi.org/10.1016/j.cell.2013.05.016
 114. Gubser PM, Bantug GR, Razik L, et al. Rapid effector function 
of memory CD8(+) T cells requires an immediate- early glyco-
lytic switch. Nat Immunol. 2013;14(10):1064- 1072. https://doi.
org/10.1038/ni.2687
 115. Tibbitt CA, Stark JM, Martens L, et al. Single- Cell RNA sequenc-
ing of the T helper cell response to house dust mites defines a 
distinct gene expression signature in airway Th2 cells. Immunity. 
2019;51(1):169- 184. https://doi.org/10.1016/j.immuni.2019.05.014
 116. Dimeloe S, Gubser P, Loeliger J, et al. Tumor- derived TGF- beta in-
hibits mitochondrial respiration to suppress IFN- gamma produc-
tion by human CD4(+) T cells. Sci Signal. 2019;12(599)eaav3334. 
https://doi.org/10.1126/scisi gnal.aav3334
 117. Mészáros G, Orbán CS, Kaposi A, et al. Altered mitochondrial 
response to activation of T- cells in neonate. Acta Physiol Hung. 
2015;102(2):216- 227. https://doi.org/10.1556/036.102.2015.2.12
 118. Aquilano G, Capretti MG, Nanni F, et al. Altered intracellular ATP pro-
duction by activated CD4+T- Cells in very preterm infants. J Immunol 
Res. 2016;8374328: https://doi.org/10.1155/2016/8374328
 119. Palin AC, Ramachandran V, Acharya S, Lewis DB. Human neonatal 
naive CD4(+) T cells have enhanced activation- dependent signaling 
regulated by the microRNA miR- 181a. J Immunol. 2013;190(6):2682- 
2691. https://doi.org/10.4049/jimmu nol.1202534
 120. Schijf MA, Kruijsen D, Bastiaans J, et al. Specific dietary oligosac-
charides increase Th1 responses in a mouse respiratory syncytial 
virus infection model. J Virol. 2012;86(21):11472- 11482. https://
doi.org/10.1128/jvi.06708 - 11
 121. Galindo- Albarrán A, López- Portales O, Gutiérrez- Reyna D, et al. 
CD8(+) T cells from human neonates are biased toward an innate 
immune response. Cell Rep. 2016;17(8):2151- 2160. https://doi.
org/10.1016/j.celrep.2016.10.056
 122. Le Campion A, Bourgeois C, Lambolez F, et al. Naive T cells pro-
liferate strongly in neonatal mice in response to self- peptide/
self- MHC complexes. P Natl Acad Sci USA. 2002;99(7):4538- 4543. 
https://doi.org/10.1073/pnas.06262 1699
 123. Schuler T, Hammerling GJ, Arnold B. Cutting edge: IL- 7- dependent 
homeostatic proliferation of CD8(+) T cells in neonatal mice allows 
the generation of long- lived natural memory T cells. J Immunol. 
2004;172(1):15- 19. https://doi.org/10.4049/jimmu nol.172.1.15
 124. Smith NL, Wissink E, Wang J, et al. Rapid proliferation and differen-
tiation impairs the development of memory CD8(+) T cells in early 
life. J Immunol. 2014;193(1):177- 184. https://doi.org/10.4049/
jimmu nol.1400553
 125. Reynaldi A, Smith NL, Schlub TE, Venturi V, Rudd BD, Davenport 
MP. Modeling the dynamics of neonatal CD8(+) T- cell responses. 
Immunol Cell Biol. 2016;94(9):838- 848. https://doi.org/10.1038/
icb.2016.47
 126. Wang J, Wissink EM, Watson NB, Smith NL, Grimson A, Rudd 
BD. Fetal and adult progenitors give rise to unique populations 
of CD8(+) T cells. Blood. 2016;128(26):3073- 3082. https://doi.
org/10.1182/blood - 2016- 06- 725366
 127. Zhang YX, Maksimovic J, Huang B, et al. Cord blood CD8(+) T cells 
have a natural propensity to express IL- 4 in a fatty acid metab-
olism and caspase activation- dependent manner. Front Immunol. 
2018;9:879. https://doi.org/10.3389/fimmu.2018.00879
 128. Jorgensen N, Persson G, Hviid TVF. The tolerogenic function 
of regulatory T cells in pregnancy and cancer. Front Immunol. 
2019;10:911. https://doi.org/10.3389/fimmu.2019.00911
 129. Cerny V, Hrdy J, Novotna O, et al. Distinct characteristics of Tregs of new-
borns of healthy and allergic mothers. PLoS ONE. 2018;13(11):e0207998. 
https://doi.org/10.1371/journ al.pone.0207998
 130. Xu LL, Kitani A, Stuelten C, McGrady G, Fuss I, Strober W. Positive and 
negative transcriptional regulation of the Foxp3 Gene is mediated by 
access and binding of the Smad3 protein to enhancer I. Immunity. 
2010;33(3):313- 325. https://doi.org/10.1016/j.immuni.2010.09.001
 131. Feng YQ, Arvey A, Chinen T, Van der Veeken JD, Gasteiger G, 
Rudensky AY. Control of the inheritance of regulatory T cell iden-
tity by a cis element in the Foxp3 locus. Cell. 2014;158(4):749- 763. 
https://doi.org/10.1016/j.cell.2014.07.031
 132. Beier UH, Angelin A, Akimova T, et al. Essential role of mitochon-
drial energy metabolism in Foxp3(+) T- regulatory cell function 
and allograft survival. Faseb J. 2015;29(6):2315- 2326. https://doi.
org/10.1096/fj.14- 268409
 133. Michalek RD, Gerriets VA, Jacobs SR, et al. Cutting edge: distinct gly-
colytic and lipid oxidative metabolic programs are essential for effector 
and regulatory CD4(+) T cell subsets. J Immunol. 2011;186(6):3299- 
3303. https://doi.org/10.4049/jimmu nol.1003613
 134. De Rosa V, Galgani M, Porcellini A, et al. Glycolysis controls the in-
duction of human regulatory T cells by modulating the expression 
of FOXP3 exon 2 splicing variants. Nat Immunol. 2015;16(11):1174- 
1184. https://doi.org/10.1038/ni.3269
 135. Borsellino G, Kleinewietfeld M, Di Mitri D, et al. Expression of 
ectonucleotidase CD39 by Foxp3(+) Treg cells: hydrolysis of ex-
tracellular ATP and immune suppression. Blood. 2007;110(4):1225- 
1232. https://doi.org/10.1182/blood - 2006- 12- 064527
 136. Timperi E, Folgori L, Amodio D, et al. Expansion of activated reg-
ulatory T cells inversely correlates with clinical severity in septic 
neonates. J Allergy Clin Immunol. 2016;137(5):1617. https://doi.
org/10.1016/j.jaci.2015.10.048
 137. Wang GH, Miyahara Y, Guo ZY, Khattar M, Stepkowski SM, Chen 
WH. "Default" generation of neonatal regulatory T cells. J Immunol. 
2010;185(1):71- 78. https://doi.org/10.4049/jimmu nol.0903806
 138. Arguello RJ, Combes AJ, Char R, et al. SCENITH: A flow 
cytometry- based method to functionally profile energy metabo-
lism with single- cell resolution. Cell Metab. 2020;32(6):1063- 1075.
e7. https://doi.org/10.1016/j.cmet.2020.11.007
How to cite this article: Holm SR, Jenkins BJ, Cronin JG, 
Jones N, Thornton CA. A role for metabolism in determining 
neonatal immune function. Pediatr Allergy Immunol. 
2021;00:1– 13. https://doi.org/10.1111/pai.13583
